Search

everythinglearnresearchcommunity

for

Search:↓

A user on dutasteride and oral minoxidil for two years has experienced worsening hair loss and an itchy scalp. Suggestions include increasing medication doses, trying other treatments like RU58841, getting a scalp biopsy, and addressing potential inflammation through diet and topical treatments.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Oral minoxidil may cause temporary facial puffiness, leading to a perception of accelerated aging, but it doesn't cause actual aging. Concerns about hair loss and treatments like minoxidil and finasteride are discussed, with suggestions to use tretinoin and sunscreen to mitigate potential side effects.

The user experienced significant hair shedding after using a dermapen at 1.5mm weekly, which they later realized was too much. They are now using a dermapen at 0.75mm weekly and are also using topical minoxidil twice daily and finasteride 1.25mg daily.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

Microneedling once a week at 1mm caused bumps, possibly scars, in the treated area. The user is considering cleaning the skin before microneedling to prevent this issue.

The user is experiencing hair loss despite using estradiol, bicalutamide, dutasteride, and topical minoxidil. They stopped minoxidil temporarily, which worsened their condition, and are considering oral minoxidil but are concerned about side effects and cost.

Switching from topical finasteride to dutasteride may cause shedding, with some users experiencing improvement after several months. Topical dutasteride is generally considered less effective than oral dutasteride.

The user started oral minoxidil, finasteride, and later switched to dutasteride, also using Nutrafol, dermastamp, and ketoconazole shampoo, but experienced increased thinning with little regrowth. Others advised patience, suggesting it takes 6-18 months to see results, and noted that initial thinning is normal when switching treatments.

The user improved diffuse thinning without finasteride by using minoxidil foam, cold showers, gentle hair drying, 2% ketoconazole, sulfate-free tea tree oil shampoo, dermastamping, and supplements like Omega-3, Vitamin-D, Biotin, Keratin, Collagen, B3, Zinc, and Magnesium. The regimen was followed for about six months under dermatologist guidance.

Dutasteride users report mixed results, with some experiencing shedding and others seeing no improvement or hair regrowth. Many users also discuss using finasteride and minoxidil, with some preferring topical treatments for better results.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Topical finasteride with hydroxypropyl chitosan shows significantly less serum absorption and minimal DHT reduction compared to oral finasteride. Users need the specific chitosan formulation to avoid side effects seen with regular ethanol+PG solutions.

The user switched from finasteride to dutasteride and experienced noticeable hair regrowth without side effects, though some users questioned the necessity of such a potent treatment given the minimal hair loss. The conversation also touched on potential side effects of dutasteride, such as reduced sperm quality, but the user reported no issues.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

The conversation discusses managing seborrheic dermatitis (sebderm) and male pattern baldness (MPB) with treatments like finasteride, coal tar shampoo, Nizoral, and oral minoxidil. Users suggest dietary changes, regular shampooing, and using antifungal products to control sebderm before considering minoxidil.

Silicone-based shampoos and conditioners may leave a layer on the scalp that could affect the absorption of topical hair loss treatments like Fluridil. The user is considering switching to silicone products to manage frizzy hair but is concerned about this potential issue.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

The user is experiencing increased hair shedding and thinning despite using Minoxidil, Finasteride, vitamins, zinc, microneedling, and Omega 3 supplements. They are seeking advice on whether this is normal and how to stop it.

The user experiences significant hair shedding during seasonal changes while using oral minoxidil 2.5mg and finasteride 1mg daily. They question if shedding miniaturized hairs is normal or if a stronger treatment is needed.

A user shared their hair regrowth success using microneedling with a dermaroller every 6 days and minoxidil, recommending betadine (povidone-iodine) before microneedling to sterilize the scalp and enhance results. Another user noted the potential risks of iodine toxicity.

The conversation discusses the scalp tension theory as a potential factor in hair loss, alongside DHT, inflammation, and other mechanisms. Treatments mentioned include finasteride, minoxidil, and botox injections, with some users exploring additional methods due to varying effectiveness.

The user switched from finasteride to dutasteride and from oral to topical minoxidil, noticing better hair regrowth with the new regimen. They experienced no side effects from dutasteride and found topical minoxidil more effective than oral.

The user is considering using topical dutasteride to prevent hair loss progression from Norwood 1 to Norwood 2 at age 25, and is concerned about the long-term effectiveness and potential shedding from the treatment. They are currently using a shampoo with caffeine, rosemary, and saw palmetto, and have noticed hair thinning and changes since age 20.

Taking dutasteride daily at higher doses results in more effective DHT suppression compared to every other day dosing, due to its dose-dependent nature and long half-life. Even at lower doses, dutasteride is more effective than finasteride for hair loss.

A user is considering adjusting their hair loss treatment, currently using 1.0mg finasteride, 2.5mg minoxidil, 5% minoxidil foam, and Nizoral 1%. They are seeking advice on whether to increase dosages or switch treatments, and if reducing dosages later would affect their progress.

The user is experiencing diffuse thinning after 10-11 months on oral finasteride and is concerned about whether this is a normal shedding phase. They have been using topical finasteride and minoxidil for over a year.